Intercept Pharma +9% as Wedbush Morgan raises price target


Intercept Pharmaceuticals (ICPT +8.9%) rises after Wedbush Morgan hikes its target price on the shares to $493, projecting gross annual peak sales of the company's OCA (obeticholic acid) treatment for alcoholic hepatitis could surpass $3B worldwide.

ICPT is supporting a phase 2 trial treating 60 patients with alcoholic hepatitis beginning in March; prevalence estimates for AH are 10%-35% of alcoholics, or 2.4M-8.4M U.S. patients.

From other sites
Comments (1)
  • jshilgendorf
    , contributor
    Comment (1) | Send Message
     
    Why did ICPT's share price go down 5% on 2/14/14?
    16 Feb 2014, 11:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs